Search Results - "Billups, Rocky"

Standardization of Outpatient Care after CAR-T Therapy across a Large Cell Therapy Network- through Technology and Decentralized Virtual Nurses: Preliminary Results by Cox, Tonya, Zahradka, Nicole, Billups, Rocky L., Blunk, Betsy, Campo, Rebecca, Carelock, Trista, Husband, Mary, LeMaistre, Charles F., Majhail, Navneet, Martin, Casey, Meissner, Sarah, Pantin, Jeremy, Perez, Meredith, Pugmire, Juliana, Ramakrishnan, Aravind, Shaughnessy, Paul, Smith, Ashleigh, Tees, Michael T., Wilkes, Matt, Yates, Megan, Battiwalla, Minoo

“…Introduction: Shifting Chimeric Antigen Receptor T-cell (CAR-T) therapy to the outpatient setting may increase patient satisfaction and inpatient capacity, and…”
Get full text

A Network Approach to Standardization of BMT Pathways by McSweeney, Peter A., MB ChB, Bachier, Carlos, MD, Berdeja, Jesus G., MD, Safah, Hana, MD, Elayan, Mohammed M., PharmD, LeMaistre, Charles F., MD, Billups, Rocky, MS, Cox, Tonya, BSN, RN, OCN

Get full text

Creating a Standardized Report to Optimize Review of Internal CIBMTR Audits across a Large Multi-Center Network by Hatley, Sarah B L, Zambrano, Hector, Cox, Tonya, Billups, Rocky, Majhail, Navneet S., Blunk, Betsy

“…The Sarah Cannon Transplant and Cellular Therapy Network (SCTCTN) includes a team of Data Analysts who work to submit required data to the CIBMTR. Collectively…”
Get full text

Programmatic Data Analyst Continuous Process Improvement (CPI) Tracking within the Sarah Cannon Transplant and Cellular Therapy Network (SCTCTN) by Zambrano, Hector, Cox, Tonya, Billups, Rocky, Majhail, Navneet S., Blunk, Betsy

“…The SCTCTN is compromised of 7 blood cancer and cellular therapy programs that collectively performed over 1600 transplant and cellular therapies in 2022…”
Get full text

Leveraging a software application to prepare for regulatory inspection within a hematopoietic cellular therapy program by Blunk, Betsy, Jawanda, Jesse, Drake, Kevin, Billups, Rocky Lee, Cox, Tonya, Dodd, Therese, LeMaistre, Charles F.

“…Abstract only 142 Background: The Sarah Cannon Blood Cancer Network (SCBCN) is comprised of seven Hematopoietic Cellular Therapy (HCT) programs. Regulations…”
Get full text

Development and implementation of clinical pathways across a network of blood cancer programs by Brougher, Laura Ione, Billups, Rocky Lee, Cox, Tonya, Dodd, Therese, LeMaistre, Charles F.

“…Abstract only 161 Background: The Sarah Cannon Blood Cancer Network (SCBCN) is comprised of 7 blood cancer and Hematopoietic Cell Therapy (HCT) programs…”
Get full text

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN) by Battiwalla, Minoo, Bachier, Carlos, Bhushan, Vikas, Eckrich, Michael J., Eghtedar, Alireza, Frangoul, Haydar, Kambhampati, Suman, Malik, Shahbaz, McSweeney, Peter A., Pantin, Jeremy, Ramakrishnan, Aravind, Safah, Hana, Shaughnessy, Paul J, Blunk, Betsy, Cox, Tonya, Billups, Rocky, Lemaistre, Charles F.

“…Background The Covid-19 pandemic has profoundly disrupted healthcare operations for vulnerable transplant and cell therapy patients. The Sarah Cannon Blood…”
Get full text

Centralized Data Management Model within the Sarah Cannon Transplant and Cellular Therapy Network (SCTCTN)- Process, Challenges and Benefits by Blunk, Betsy, Zambrano, Hector, Billups, Rocky, Majhail, Navneet S., Bosch, Connie, Culver, Jennifer, Sinnema, Julie, Wood, Mary, Younger, Leslie, Olivarez, Angelica, Turner, Veloria, Bays, Nora Kristin, Hatley, Sarah B L, Jordan, Tiffany, Cox, Tonya

“…The SCTCTN comprises 7 transplant and cellular therapy programs that collectively performed 1,600 transplants and cellular therapies in 2022. There are 20…”
Get full text

Carvykti (cilta-cel) Real World Outcomes across the Sarah Cannon Transplant Cell Therapy Network by Gregory, Tara, Blunk, Betsy, Cox, Ms. Tonya, Billups, Rocky, Mattlin, Meredith, Martin, Casey, Berdeja, Jesús G, Bhushan, Vikas, LeMaistre, Dr. C. Fred, Ramakrishnan, Dr. Aravind, Shaughnessy, Paul J., Majhail, Navneet S., Battiwalla, Minoo

“…CARVYKTI (ciltacabtagene autoleucel, cilta-cel) is approved for relapsed and refractory multiple myeloma (RRMM). Here we describe real world outcomes of…”
Get full text

A Standardized Cell Dose to Optimize Unrelated Donor Peripheral Blood Stem Cell (PBSC) Collections: A Prospective Study between the Sarah Cannon Transplant and Cellular Therapy Network (SCTCTN) and the National Marrow Donor Program (NMDP) by Rao, Uttam, Blunk, Betsy, Martin, Casey, Stefanski, Dr. Heather E., Devine, Steven M., Koretzky, Lindsey, Bhushan, Vikas, Billups, Rocky, LeMaistre, Dr. C. Fred, Gregory, Tara, Pantin, Jeremy, Ramakrishnan, Dr. Aravind, Shaughnessy, Paul J., Tees, Michael, Majhail, Navneet S., Battiwalla, Minoo

“…Allogeneic hematopoietic cell transplantation (HCT) depends on the capacity of donor hematopoietic stem cells to reconstitute recipient hematopoiesis after…”
Get full text

Access Barriers to Anti-CD19+ CART-Cell Therapy for NHL Across a Community Transplant and Cellular Therapy Network by Battiwalla, Minoo, Tees, Michael T, Flinn, Ian W, Pantin, Jeremy, Berdeja, Jesus G, Gregory, Tara, Maris, Michael B, Bhushan, Vikas, Vance, M.D, Estil, Mathews, John, Bachier, Carlos, Shaughnessy, Paul J, Ramakrishnan, Aravind, Malik, Shahbaz A, Mori, Shahram, Martin, Casey, Billups, Rocky, Blunk, Betsy, LeMaistre, Charles F, Majhail, Navneet S

“…We analyzed access barriers to anti-CD19+ chimeric antigen receptor T-cells (CART) for non-Hodgkin lymphoma (NHL) within a community-based transplant and cell…”
Get full text

Remote Patient Monitoring (RPM) Technology with Centralized Virtual Nurse Monitoring for Safe Delivery of Outpatient Chimeric Antigen Receptor T-Cell (CAR-T) Therapy across Multiple Sarah Cannon Transplant and Cellular Therapy Network Programs by Cox, Tonya, Carelock, Trista, Zahradka, Nicole, Pugmire, Juliana, Wilkes, Matt, Campo, Rebecca, Garber, Sarah, Yates, Megan, Perez, Meredith, Husband, Mary, Martin, Casey, Blunk, Betsy, Billups, Rocky, LeMaistre, Dr. C. Fred, Pantin, Jeremy, Ramakrishnan, Dr. Aravind, Shaughnessy, Paul J., Tees, Michael, Majhail, Navneet S., Battiwalla, Minoo

“…Outpatient CAR-T therapy may enhance patient experience, optimize center capacity, and reduce risk of hospital-acquired infections. It requires monitoring…”
Get full text

Outpatient Administration of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Non-Hodgkin Lymphoma (NHL), in a Large Multi-Center Network by Tees, Michael, Agrawal, Tarun, Martin, Casey, Cox, Ms. Tonya, Blunk, Betsy, Billups, Rocky, Bachier, Carlos R., Bhushan, Vikas, Cruz, Jose C Carlos, Flinn, Ian W., Gregory, Tara, LeMaistre, Dr. C. Fred, Malik, Shahbaz, Mathews, John, Maris, Michael, Mountjoy, Luke, Pantin, Jeremy, Ramakrishnan, Dr. Aravind, Rao, Uttam, Schade, Henning, Shaughnessy, Paul J., Vance, Estil, Zoghi, Behyar, Majhail, Navneet S., Battiwalla, Minoo

“…Patients receiving CAR T-cell therapy for NHL are often hospitalized and need close monitoring for cytokine release syndrome (CRS) and neurotoxicity (ICANS)…”
Get full text

Access Barriers for Anti-CD19+ Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Non-Hodgkin Lymphoma (NHL) across a Large Community Transplant and Cellular Therapy Network by Battiwalla, Minoo, Tees, Michael, Flinn, Ian W., Pantin, Jeremy, Berdeja, Jesús, Gregory, Tara, Maris, Michael, Bhushan, Vikas, Vance, Estil, Mathews, John, Bachier, Carlos, Shaughnessy, Paul J., Ramakrishnan, Dr. Aravind, Malik, Shahbaz, Mori, Shahram, Billups, Rocky, Blunk, Betsy, LeMaistre, Dr. C. Fred, Majhail, Navneet S.

Get full text

Outcomes for Anti-CD19+ Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Non Hodgkin Lymphoma (NHL) across a Large Community Transplant and Cellular Therapy Network by Battiwalla, Minoo, Tees, Michael, Flinn, Ian W., Pantin, Jeremy, Gregory, Tara, Maris, Michael, Bhushan, Vikas, Vance, Estil, Mathews, John, Bachier, Carlos, Shaughnessy, Paul J., Ramakrishnan, Dr. Aravind, Malik, Shahbaz, Mori, Shahram, Gergis, Usama, Billups, Rocky, Blunk, Betsy, LeMaistre, Dr. C. Fred, Majhail, Navneet S.

Get full text

273 - Outcomes for Anti-CD19+ Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Non Hodgkin Lymphoma (NHL) across a Large Community Transplant and Cellular Therapy Network by Battiwalla, Minoo, Tees, Michael, Flinn, Ian W., Pantin, Jeremy, Gregory, Tara, Maris, Michael, Bhushan, Vikas, Vance, Estil, Mathews, John, Bachier, Carlos, Shaughnessy, Paul J., Ramakrishnan, Dr. Aravind, Malik, Shahbaz, Mori, Shahram, Gergis, Usama, Billups, Rocky, Blunk, Betsy, LeMaistre, Dr. C. Fred, Majhail, Navneet S.

Get full text

64 - Access Barriers for Anti-CD19+ Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Non-Hodgkin Lymphoma (NHL) across a Large Community Transplant and Cellular Therapy Network by Battiwalla, Minoo, Tees, Michael, Flinn, Ian W., Pantin, Jeremy, Berdeja, Jesús, Gregory, Tara, Maris, Michael, Bhushan, Vikas, Vance, Estil, Mathews, John, Bachier, Carlos, Shaughnessy, Paul J., Ramakrishnan, Dr. Aravind, Malik, Shahbaz, Mori, Shahram, Billups, Rocky, Blunk, Betsy, LeMaistre, Dr. C. Fred, Majhail, Navneet S.

Get full text

Preparing for the Unthinkable: Emergency Preparedness for the Hematopoietic Cell Transplant Program by Wingard, John R., Leahigh, Alan K., Confer, Dennis, Edwards, John, Billups, Rocky L., van den Brink, Marcel, Keating, Armand

“…Emergencies come at the most inopportune times. Some are totally unexpected, others come with short warnings. Although rare, an emergency comes with the…”
Get full text

Successful Virtual Mock FACT Inspection: How Sarah Cannon Blood Cancer Network and Texas Transplant Institute in San Antonio and Austin Made It Work by Dodd, Therese, Bachier, Carlos R., Bedi, Neru, Billups, Rocky, Blunk, Betsy, Cantwell, Lisa, Eckrich, Michael J, Frangoul, Haydar, Ginn, Cody, Kiehne, Lisa, Meadors, Sara, Procter, Alison, Ramakrishnan, Aravind, Robles, Robert, Shaughnessy, Paul J., Ward, Sandra, LeMaistre, C. Fred

Get full text

Measuring the Effectiveness of CAR T-CELL Therapy Nursing Education by Carelock, Trista, Cox, Tonya, Billups, Rocky, Hartman, Lisa, Marty, Kerensa, DeMeyer, Elaine S.

“…Chimeric antigen receptor (CAR) T-Cell therapy standardized professional education is critical to help oncology team members understand the science behind this…”
Get full text